Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene Variant Increases Risk of Age-Related Macular Degeneration

11.03.2005


Researchers at Duke University Medical Center and Vanderbilt University Medical Center have pinpointed the first major gene that determines an individual’s risk for developing age-related macular degeneration (AMD). The chronic, progressive disease -- which affects as many as 15 million people in the United States -- is the leading cause of visual impairment and legal blindness in the elderly.



A common variant of the gene, called complement factor H (CFH), explains approximately 43 percent of the risk of AMD among older adults, the researchers estimated. The team identified the disease-related gene after screening 182 families affected by AMD and 495 other individuals with the condition. The researchers will report their findings in a forthcoming issue of Science (published online March 10, 2005, in Science Express).

The genetic advance sheds light on the mechanisms underlying the disease and could lead to new avenues for treatment, the researchers said. The finding might also yield methods for identifying those patients at the greatest risk for developing the condition before symptoms arise, when therapies and changes in lifestyle might be most effective in slowing the disease progression. "Macular degeneration is an important cause of blindness and loss of independence in the elderly," said Margaret Pericak-Vance, Ph.D., director of the Duke Center for Human Genetics and senior author of the report. "This gene opens the door to a whole new understanding of the factors that contribute to this disease. "The finding may ultimately lead to new methods for identifying those at high risk for macular degeneration and suggests new pathways for drug development," she added.


AMD causes progressive impairment of central vision, and is the most common cause of legal blindness in Americans over the age of 55. The disease causes damage to the retina, a thin layer of nervous tissue that lines the inside of the eye. The primary site of damage occurs in the central retina, a portion called the macula.

The retina functions like film in a camera, explained ophthalmologist Eric Postel, M.D., of the Duke University Eye Center. Without proper retinal function, images cannot be captured and sent to the brain. The macula is critical for fine, detailed vision. In patients with severe AMD, progressive blurring and loss of central vision due to damage of the macula may leave people unable to perform everyday activities such as driving, reading, writing checks and recognizing faces, he said. "Fifteen million people in the United States have AMD and 1.5 million have the most severe form," said Postel, the head clinician on the study. "By the year 2030, as the baby boomer generation ages, the number of people with AMD is expected to double."

AMD exists in two forms: the "dry" form and more severe "wet" form. In the dry form, degeneration of the macula can cause slow, progressive vision loss over the course of months to years. While there is no cure, vitamin supplements have been shown to slow the disease in some individuals with this milder form.

In ten percent of patients, the disease progresses to the wet form in which abnormal blood vessels under the macula leak blood and fluid causing rapid damage and a precipitous loss of vision. Patients with wet AMD can receive several treatments to prevent further vision loss -- including laser surgery and recently approved injections of a drug into the eye. However, available therapies usually can only stall the disease progression, Postel said. None effectively reverse the course of the disease.

While the underlying causes of AMD had remained largely unknown, risk factors include age, smoking, high blood pressure, obesity and diet, said Pericak-Vance. In addition to such environmental factors, evidence from family and twin studies had indicated a significant genetic contribution to the disease, she added.

Earlier studies by the Duke and Vanderbilt teams and others had linked AMD risk to a particular region on chromosome 1. To identify the gene responsible, the researchers examined two independent data sets: the first contained 182 families including members with and without AMD and the second contained 495 individuals with AMD and 185 unrelated individuals not affected by the disease.

The researchers zeroed in on a smaller region of chromosome 1 with a strong association to the disease in both data sets. Further DNA sequencing of the CFH gene that is within that region revealed that individuals with one or more copies of a particular gene variant were more likely to have AMD compared to those with other versions of the gene, they reported. When the researchers restricted the analysis to individuals with the more severe, wet form of AMD, the association between the gene variant and the disease became even stronger.

The researchers estimated that the CFH variant may be responsible for up to 43 percent of all cases of AMD. Earlier studies had suggested that CFH may play a role in protecting blood vessels from inflammation and damage, a function which might explain its role in AMD, the researchers said. "We knew that chronic inflammation played a role in macular degeneration, but we didn’t know if that was a primary cause of the disease or a secondary symptom," said Jonathan Haines, Ph.D., of Vanderbilt Center for Human Genetics Research and first author on the report. "The finding that complement factor H is an important contributor to the disease suggests that inflammation may be a more important aspect of the disease than had previously been appreciated."

Given that the gene plays such a large role in AMD, further studies of CFH and the cellular components with which it interacts might lead to a rapid increase in understanding of the biology of the disease, the researchers added. That information, in turn, should allow scientists to advance on new treatments and preventive therapies.

Collaborators on the study include Michael Hauser, Silke Schmidt, William Scott, Paul Gallins, Shu Ying Kwan, Maher Noureddine and John Gilbert, of the Duke Center for Human Genetics; Lana Olson, Kylee Spencer, Nathalie Schnetz-Boutaud and Anita Agarwal, of the Vanderbilt University Medical Center. The National Eye Institute supported the work. Additional resources came from the National Institute on Aging and the National Center for Research Resources to Vanderbilt University.

Kendall Morgan | EurekAlert!
Further information:
http://www.duke.edu

More articles from Life Sciences:

nachricht Scientists decipher key principle behind reaction of metalloenzymes
15.01.2018 | Rheinisch-Westfälische Technische Hochschule Aachen

nachricht New method to map miniature brain circuits
15.01.2018 | The Francis Crick Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

Im Focus: Autoimmune Reaction Successfully Halted in Early Stage Islet Autoimmunity

Scientists at Helmholtz Zentrum München have discovered a mechanism that amplifies the autoimmune reaction in an early stage of pancreatic islet autoimmunity prior to the progression to clinical type 1 diabetes. If the researchers blocked the corresponding molecules, the immune system was significantly less active. The study was conducted under the auspices of the German Center for Diabetes Research (DZD) and was published in the journal ‘Science Translational Medicine’.

Type 1 diabetes is the most common metabolic disease in childhood and adolescence. In this disease, the body's own immune system attacks and destroys the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fachtagung analytica conference 2018

15.01.2018 | Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

 
Latest News

Black hole spin cranks-up radio volume

15.01.2018 | Physics and Astronomy

A matter of mobility: multidisciplinary paper suggests new strategy for drug discovery

15.01.2018 | Life Sciences

New method to map miniature brain circuits

15.01.2018 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>